NCT04627051Unknown不适用
A Prospective, Single-Centre Study Investigating the Clinical Use and Safety of the Jetstream Atherectomy With Drug Coated Balloon (Ranger) for the Treatment of Dysfunctional Arterio-Venous Graft Stenosis
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Target Lesion Primary Patency (TLPP) through 6 months
研究概览
简要总结
This single-centre, single-arm, prospective study will enroll 30 subjects presenting with clinical and hemodynamic abnormalities in arteriovenous graft (AVG) in the arm. Subjects will be treated with the Jetstream™ atherectomy device and Ranger™ Drug Coated Balloons (DCB). Subjects will be followed up clinically via office visit or phone visit at 6 and 12 months post procedure. This study is to demonstrate safety and assess the clinical use and outcomes of the Jetstream ™atherectomy device and Ranger™ DCB for the treatment of dysfunctional AV graft.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-breastfeeding female ≥18 years of age;
- •Subject is willing to provide informed consent, and is willing to comply with the protocol-required follow up visits;
- •Target lesion must be a mature arteriovenous graft presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines;
- •Subject has a target lesion at the venous anastomosis of the AVG;
- •Successful crossing of the stenosis;
- •Each lesion length is ≤20mm, which may include tandem lesions that are ≤20mm apart
排除标准
- •Subject is currently participating in an investigational drug or device study which has not yet reached its primary endpoint or was previously enrolled into this study;
- •Subject has a non-controllable allergy to contrast;
- •Subject has more than 3 lesions in the access circuit requiring intervention;
- •Target lesion diameter >10mm;
- •A thrombosed access or an access with a thrombosis treated ≤30 days prior to the index procedure;
- •Prior surgical interventions of the access site ≤30 days before the index procedure;
- •Target lesion is located within a bare metal or covered stent.
结局指标
主要结局
Target Lesion Primary Patency (TLPP) through 6 months
时间窗: within 6 months post intervention
50% re-stenosis of the target lesion
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R MutationNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorNCT06102928Kunming Medical University30
进行中（未招募）
不适用
Study for Evaluating the Efficacy of Ciprofol in Patients Under Narcotic Sleep With Chronic InsomniaChronic InsomniaNCT04958382Sichuan Provincial People's Hospital30
已完成
不适用
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type PsoriasisPsoriasisNCT00800982University of California, San Francisco30
终止
1 期
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid TumorsSolid TumorNCT05430360Grit Biotechnology2
已完成
1 期
First in Man Experience With a Drug Eluting Stent in De Novo Coronary Artery LesionsCoronary Artery DiseaseNCT01214148Biotronik AG30